Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The growth hormone (GH)-insulin-like growth factor axis during testosterone replacement therapy in GH-treated hypopituitary males
Autore:
Fisker, S; Norrelund, H; Juul, A; Skakkebaek, NE; Christiansen, JS; Jorgensen, JOL;
Indirizzi:
Aarhus Univ Hosp, Med Dept Endocrinol & Diabet M, DK-8000 Aarhus, Denmark Aarhus Univ Hosp Aarhus Denmark DK-8000 iabet M, DK-8000 Aarhus, Denmark
Titolo Testata:
GROWTH HORMONE & IGF RESEARCH
fascicolo: 2, volume: 11, anno: 2001,
pagine: 104 - 109
SICI:
1096-6374(200104)11:2<104:TGH(GF>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
RECEPTOR GENE-EXPRESSION; FACTOR-I; BINDING PROTEIN; IGF-I; PRECOCIOUS PUBERTY; DEFICIENT ADULTS; HUMAN INSULIN; HUMAN SERUM; WOMEN; SECRETION;
Keywords:
testosterone; insulin-like growth factor-I; growth hormone deficiency;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Fisker, S Aarhus Kommune Hosp, Med Dept M, Norrebrogade 44, DK-8000 AarhusC, Denmark Aarhus Kommune Hosp Norrebrogade 44 Aarhus Denmark C C, Denmark
Citazione:
S. Fisker et al., "The growth hormone (GH)-insulin-like growth factor axis during testosterone replacement therapy in GH-treated hypopituitary males", GROWTH H I, 11(2), 2001, pp. 104-109

Abstract

Several studies suggest a direct effect of sex steroids on insulin-like growth factor-I (IGF-I) production. Oestrogen has been hypothesized directly to inhibit hepatic IGF-l production, but the role of androgens is not clarified. We aimed to investigate whether testosterone exerts a pituitary-independent effect on lGF-l and related parameters. Eight adult hypopituitary men (39.9 +/-5.7 years) receiving growth hormone (GH) and testosterone replacement therapy (250 mg testosterone enantate every fourth week) participatedin this prospective study. Frequent blood samples were drawn over a 5 weekperiod in relation to two testosterone injections. Mean baseline IGF-l levels were 352 +/- 135 mug/L, and they remained unaltered during the study period (analysis of variance (ANOVA), P= 0.88). Free IGF-l levels did not change either (ANOVA, P = 0.35). Serum lGF binding protein-3 (IGFBP-3) and acid-labile subunit decreased (ANOVA, P = 0.04 and P = 0.02 respectively) but post hoc analysis did not reveal a particular difference between days. IGFBP-1 increased following testosterone administration (ANOVA, P = 0.05), whereas GH binding protein levels tended to decrease following testosterone administration (ANOVA, P= 0.08). Prostate-specific antigen tended slightly to increase after each testosterone injection (ANOVA, P = 0.08, post hoc, NS). We conclude that major changes in total lGF-1 are not induced during conventional intramuscular testosterone replacement in GH-treated hypopituitary males, suggesting that testosterone effects on IGF-l are likely to be secondary to a stimulation of endogenous GH release. (C) 2001 Harcourt Publishers Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/06/20 alle ore 09:48:21